News

The Foundation for Sarcoidosis Research (FSR) is funding a new research project that aims to find biological markers that could help identify people with sarcoidosis who are at risk of developing advanced lung disease. The work will be led by Christen Vagts, MD, an early career physician scientist…

The U.S. Food and Drug Administration (FDA) has greenlit a month-old request by Molecure to begin a Phase 2 clinical trial of its investigational oral therapy OATD-01 in people with pulmonary sarcoidosis. The proof-of-concept study, which is ready to launch, according to Molecure, will be the first…

Patterns of multiorgan involvement in African Americans with sarcoidosis differ from those of Americans of European ancestry, a study suggests. But in both groups, certain genetic mutations are associated with specific patterns of organ involvement. Collectively, its findings “support ancestry-specific differences likely resulting from distinct social, cultural, and environmental…

Cardiac sarcoidosis affects slightly more women, but men with the disease are at higher risk of potentially fatal heart rhythm abnormalities, according to a study in Japan. The findings suggest more aggressive preventive treatment for heart problems may be warranted for men with cardiac sarcoidosis, the researchers noted in “…

Meitheal Pharmaceuticals has entered into an agreement with Xentria to market XTMAB-16, the investigational treatment for pulmonary sarcoidosis, should it be approved in the future. Under the terms of the agreement, Meitheal gains the sole rights to sell and distribute XTMAB-16 in North America. Xentria retains the…

Molecure is seeking permission from the U.S. Food and Drug Administration (FDA) to conduct a Phase 2 clinical trial of its oral treatment candidate OATD-01 in people with pulmonary sarcoidosis. The request came in the form of an investigational new drug application (IND) submitted to the FDA. Should…

Sarcoidosis patients who are male or carry a genetic variation called HLA-DRB1*07 are more likely to have lymphopenia — low levels of white blood cells called lymphocytes — a known risk factor for more severe disease. That is according to a study, “Peripheral blood lymphopenia in sarcoidosis…

Greater exposure to the experimental treatment efzofitimod led to a more pronounced improvement in lung function for people with pulmonary sarcoidosis in a Phase 1/2 clinical trial, according to a new analysis. Scientists at aTyr Pharma, the company developing the first-in-class immunomodulatory therapy, presented their findings at…

Despite advances in testing, fewer than one of every six people evaluated for suspected neurosarcoidosis — sarcoidosis affecting the nervous system — received a definite diagnosis of the inflammatory disorder, according to a 30-year study in Sweden. A confirmed neurosarcoidosis diagnosis in those cases was made only following a…

Patient and physician education, trust-building, and support mechanisms are needed to reduce barriers to clinical trial participation for Black people with sarcoidosis, according to a paper by the Foundation for Sarcoidosis Research (FRS). The white paper was titled “Ignore No More Campaign on Clinical Trials…